⏳ Fetching live dividend data...
Home › Calculator › CBIXF Dividend Calculator 2026
Carna Biosciences, Inc. · OTC
Price: $10.75 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in CBIXF → $55.1K in 10 years · $720.04/month
Carna Biosciences, Inc., headquartered in Kobe, Japan, and established in 2003, is a clinical-stage biopharmaceutical company. Its core mission is to discover and advance innovative drug treatments specifically targeting critical unmet medical needs. Beyond its therapeutic pipeline, the company offers a comprehensive suite of specialized research reagents and tools. These include various kinase proteins and their corresponding substrates, alongside a range of kinase protein assay kits and stable cell lines. They also provide biotinylated kinases, which are instrumental for detailed studies of kinase-molecule interactions. Carna Biosciences further extends its expertise through a diverse portfolio of contract research services. These encompass extensive assay development and screening capabilities, such as profiling, NanoBRET TE and ClariCELL intracellular kinase cell-based assays, live-cell kinase assays, and tyrosine kinase cell-based assays. The company also supports protein detection and interaction studies, crystallization, and weak affinity chromatography, in addition to offering custom production of ultra-pure proteins specifically tailored for crystallographic analysis. A significant part of Carna Biosciences' strategic focus is dedicated to advancing a pipeline of novel therapeutic candidates for various diseases. Key among these is AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase, which is currently undergoing preclinical evaluation for oncology indications. Another promising asset, AS-0871, is a small molecule drug targeting inflammatory and immune disorders, presently in Phase 1 clinical trials. Furthermore, the company is progressing AS-1763, an orally administered, non-covalent inhibitor in preclinical development, aimed at treating chronic lymphocytic leukemia (CLL) and other B-cell malignancies. To further its objectives, Carna Biosciences actively engages in strategic collaborations with prominent partners, including Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open CBIXF position with:
Real after-tax yield depends on where you live and how you hold CBIXF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 18.60% | 15.80% | $1,860 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 15.81% | 13.01% | $1,581 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 14.88% | 12.08% | $1,488 / yr |
| 🇬🇧 UK ISA | 0% | 18.60% | 15.80% | $1,860 / yr |
| 🇬🇧 UK Taxable | 8.75% | 16.97% | 14.17% | $1,697 / yr |
| 🇨🇦 TFSA | 0% | 18.60% | 15.80% | $1,860 / yr |
| 🇨🇦 CA Taxable | 25% | 13.95% | 11.15% | $1,395 / yr |
| 🇦🇺 Super (pension) | 15% | 15.81% | 13.01% | $1,581 / yr |
| 🇦🇺 AU Taxable | 30% | 13.02% | 10.22% | $1,302 / yr |
| 🇩🇪 DE Taxable | 26.375% | 13.69% | 10.89% | $1,369 / yr |
| 🇫🇷 FR Taxable | 30% | 13.02% | 10.22% | $1,302 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
CBIXF pays quarterly — 4 times per year. Next ex-div: TBD.
How CBIXF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CBIXF sourced from FMP /financial-growth endpoint — real data, not estimates.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CBIXF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Carna Biosciences, Inc. (CBIXF) is a healthcare stock currently trading at $10.75 with a dividend yield of 18.60%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever